- Home
- NXRT vs SEPN Comparison
NXRT vs SEPN Comparison
Compare NXRT & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXRT
- SEPN
- Stock Information
- Founded
- NXRT 2014
- SEPN 2022
- Country
- NXRT United States
- SEPN United States
- Employees
- NXRT N/A
- SEPN N/A
- Industry
- NXRT Real Estate Investment Trusts
- SEPN
- Sector
- NXRT Real Estate
- SEPN
- Exchange
- NXRT Nasdaq
- SEPN NYSE
- Market Cap
- NXRT 1.2B
- SEPN 1.0B
- IPO Year
- NXRT N/A
- SEPN 2024
- Fundamental
- Price
- NXRT $43.49
- SEPN $23.30
- Analyst Decision
- NXRT Buy
- SEPN Strong Buy
- Analyst Count
- NXRT 5
- SEPN 4
- Target Price
- NXRT $49.00
- SEPN $43.67
- AVG Volume (30 Days)
- NXRT 92.8K
- SEPN 226.8K
- Earning Date
- NXRT 10-29-2024
- SEPN 11-20-2024
- Dividend Yield
- NXRT 4.54%
- SEPN N/A
- EPS Growth
- NXRT 54.64
- SEPN N/A
- EPS
- NXRT 1.77
- SEPN N/A
- Revenue
- NXRT $264,974,000.00
- SEPN $981,000.00
- Revenue This Year
- NXRT N/A
- SEPN N/A
- Revenue Next Year
- NXRT $0.54
- SEPN N/A
- P/E Ratio
- NXRT $25.75
- SEPN N/A
- Revenue Growth
- NXRT N/A
- SEPN N/A
- 52 Week Low
- NXRT $28.20
- SEPN $18.62
- 52 Week High
- NXRT $48.37
- SEPN $27.47
- Technical
- Relative Strength Index (RSI)
- NXRT 43.52
- SEPN N/A
- Support Level
- NXRT $44.31
- SEPN N/A
- Resistance Level
- NXRT $46.15
- SEPN N/A
- Average True Range (ATR)
- NXRT 0.90
- SEPN 0.00
- MACD
- NXRT -0.30
- SEPN 0.00
- Stochastic Oscillator
- NXRT 14.08
- SEPN 0.00
About NXRT NexPoint Residential Trust Inc.
NexPoint Residential Trust Inc is a real estate investment trust company. Its objectives are to maximize the cash flow and value of properties owned, acquire properties with cash flow growth potential, provide quarterly cash distributions, and achieve long-term capital appreciation for stockholders. The company seeks to achieve these objectives through targeted management and a capex value-add program. It focuses on acquiring multifamily properties in markets with attractive job growth and household formation fundamentals predominantly in the Southeastern and Southwestern United States. The company generates revenue from the rental of multifamily properties.
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR.